Pharmacoeconomic Analysis of Docetaxel in the Adjuvant Therapy of Breast Cancer

Value in Health - United Kingdom
doi 10.1016/j.jval.2013.03.642
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Pcn180 - Pharmacoeconomic Assessment of Fulvestrant Versus Dd (Doxorubicin, Docetaxel) Therapy in Postmenopausal Women With Metastatic Er (+) Her2 (-) Breast Cancer in Ukraine

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Breast-Cancer Adjuvant Therapy With Zoledronic Acid

New England Journal of Medicine
Medicine
2012English

Adjuvant Endocrine Therapy in Early Postmenopausal Breast Cancer

Breast Care
SurgeryOncology
2008English

Bisphosphonates as Adjuvant Therapy for Breast Cancer

Women's Health
Medicine
2006English

P53 Expression and the Result of Adjuvant Therapy of Breast Cancer

Acta Oncologica
Nuclear MedicineRadiologyHematologyOncologyMedicineImaging
1995English

Understanding Adjuvant Endocrine Therapy Persistence in Breast Cancer Survivors

BMC Cancer
Cancer ResearchOncologyGenetics
2018English

Adjuvant Therapy After Preoperative Treatment for Breast Cancer

Breast Cancer Research
Cancer ResearchOncology
2009English

Long Term Adjuvant Therapy for Primary Breast Cancer

BMJ
1996English

Current Treatment of Early Breast Cancer: Adjuvant and Neoadjuvant Therapy

F1000Research
GeneticsMolecular BiologyPharmacologyBiochemistryMicrobiology ImmunologyMedicineToxicologyPharmaceutics
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy